Skip to content
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
BioTechGrid BioTechGrid
  • Home
  • Biotechnology
  • Medical Technology
  • Research
  • Genetics
  • Press Releases
    • Business Wire
    • GlobeNewswire
    • PRNewswire
  • Contact
  • Home
  • Biotechnology
  • Novartis, Bristol Myers halt autoimmune CAR-T trials due to adverse events

Novartis, Bristol Myers halt autoimmune CAR-T trials due to adverse events

August 31, 2026Posted inBiotechnology

Novartis and Bristol Myers Squibb have halted several CAR-T trials in autoimmune diseases due to immune-related adverse events, Fierce has learned.

Post navigation

Previous Post
key-immune-cells-identified-that-could-strengthen-flu-vaccines Key Immune Cells Identified That Could Strengthen Flu Vaccines
Next Post
‘One-Two Punch’ Targets Resistance Mechanism in Aggressive Triple-Negative Breast Cancer ‘one-two-punch’-targets-resistance-mechanism-in-aggressive-triple-negative-breast-cancer

Recent Posts

  • Mine-Adapted Bacteria Enhance Nutrient Uptake and Growth in Maize and Tomato
  • Mitochondrial Damage and Ferroptosis Interlock to Drive Bone Loss in Osteoporosis
  • Italian RAADS-R Validation Identifies Candidate Cut-Offs in Adult Case-Control Study
  • Posttraumatic Stress From Child-Related Trauma Predicts Poorer Perceived Health in Mothers
  • Pilot Study Links Cosmetic Scalp Care to Improved Mood and Sleep Metrics

Archives

  • November 2026
  • October 2026
  • September 2026
  • August 2026
  • July 2026
  • September 2024
  • August 2024
  • March 2024
  • September 2023

Privacy Policy    Terms

Scroll to Top